Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeTopicsBioprocessingCell Therapy Company Aims to Pioneer Analytics Automation
Credit: Yuichiro Chino/ Getty Images
BlueRock Therapeutics says it has developed an automated system for high-throughput auditing of this relatively new class of therapeutics. According to BlueRock, the system, which accommodates cell culture, liquid handling, and processing with small volume samples, is designed to fill a gap between the need for solutions and those currently available.
“In modalities like small molecules, platforms are more or less plug-and-play and so are the systems used for automation, but there’s been a gap as people have moved to this new modality,” explains Ronnie Lum, PhD, director of analytical and quality control.
To contribute to the growing cell therapy ecosystem, Lum and his team have adapted readily available tools and systems to the smaller batch volumes produced in cell therapies.
“This field is new,” he says. “We want to be a pioneer and really push the envelope of where we can go with automation. Specifically in the analytical audit space, there aren’t many solutions out there, so we’ve really put the effort in.”
The customized system has been designed and built in collaboration with Hamilton Robotics and involves adapting the company’s existing analytical systems to liquid handling and, they hope, high-throughput automation with the aim of scaling up to commercial volumes in this new field.
The company hopes their new system will help them reach the market faster with their own pipeline of therapies and can be adapted easily afterward to the processes involved with their new products.
In general, they hope these technologies will drive down the cost of analytics across the cell therapy industry by reducing the sample volumes needed for testing and, thus, the cost of reagents used in complex assays.
Going forward, BlueRock Therapeutics urges other companies to join them in developing systems to address technological gaps. “We’re willing to push the boundaries by investing in these technologies and trying to innovate.”
InsightsAutomationCell cultureCell therapyHigh throughput screeningSmall moleculesBlueRock TherapeuticsAlso of Interest
Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB TechnologySmarter Cell Culture Starts with Better MediaCAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research CollaborationTop 10 Contract Development and Manufacturing Organizations 202610 CDMO Up & Comers 2026Harnessing Real-Time DataRelated Media
Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and SustainabilityRobots on the Red Line: A Video Update from SLAS 2026Smart Vector Design for Improved Cell and Gene TherapiesFrom Functional Genomics to Cell Therapy: The Role of CRISPR-Based Gene EditingPrecision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene TherapiesASGCT 2024: A Video Update from BaltimoreTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
Copyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
